San Diego protein‑sequencing company Encodia ceased operations and began auctioning laboratory equipment after filing an assignment for the benefit of creditors in California. The collapse halts development of Encodia’s ProteoCode platform, which tagged peptides with DNA for readout by next‑generation sequencing and had raised about $75 million in a Series C. Founders included former Illumina and 454 veterans; the shutdown underscores financing and commercialization challenges for emerging proteomics sequencing technologies. Sources indicated the company closed late last year, with staff departures and asset dispositions ongoing as buyers assess mass spectrometers, sequencers and liquid handlers.